文献速递免疫规划传染病防控与疫情报告

通过白细胞基因离体激活(EAGL)试验纵向监测细胞免疫,揭示mRNA新冠疫苗对抗突破性症状效力的潜在标志物

Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
PubMed 文献 · Vaccine · 2025-11-06

研究采用高通量白细胞基因离体激活(EAGL)试验,纵向监测日本接种者接种mRNA新冠疫苗后的T细胞反应。结果显示疫苗诱导的细胞免疫持续时间长于抗体滴度,较低抗体滴度往往先于感染出现,而细胞免疫反应与突破性感染发生无关;在突破性病例中,无症状者Th1/CD8+ T细胞细胞因子反应(IFNG、IL2、TNFSF2)有高于轻症者的趋势但未达统计学显著。转录组分析发现CXCL9表达降低与持续症状相关,≥55岁者Th1/CD8+ T细胞细胞因子表达显著下降且CXCL9低于持续症状相关阈值。

要点

  • 疫苗诱导的细胞免疫持续时间长于抗体滴度。
  • 较低抗体滴度往往先于感染出现,细胞免疫反应与突破性感染发生无关。
  • ≥55岁者Th1/CD8+ T细胞细胞因子表达显著下降,CXCL9表达低于持续症状相关阈值。

核心结论

  • 细胞免疫读数,特别是IFNG联合CXCL9,可能作为疫苗介导症状减轻的探索性相关指标。
  • EAGL试验是高效、可扩展的高通量评估疫苗诱导细胞免疫的平台,有望作为个体水平疫苗效力预测工具。

研究设计与样本

  • 研究采用EAGL试验评估接种mRNA新冠疫苗的日本供者血样中的T细胞反应,在接种后不同间隔纵向追踪免疫。

主要发现

  • 疫苗诱导的细胞免疫持续时间长于抗体滴度。
  • 较低抗体滴度往往先于感染出现,而细胞免疫反应与突破性感染发生无关。
  • 在突破性病例中,无症状供者的Th1/CD8+ T细胞细胞因子反应(IFNG、IL2、TNFSF2)有高于轻症者的趋势,但差异未达统计学显著。
  • 转录组分析发现CXCL9是疾病结局的潜在新标志物,其表达降低与持续症状相关。
  • 在≥55岁个体中,Th1/CD8+ T细胞细胞因子表达显著下降,CXCL9表达降至与持续症状相关的阈值以下;相比之下,未观察到体液免疫指标随年龄一致下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

mRNA vaccines have demonstrated broad effectiveness against coronavirus disease 2019 (COVID-19); nonetheless, substantial interindividual variability in vaccine-induced immunity limits our ability to predict protective efficacy at the individual level, particularly against severe manifestations of the disease. Cellular immune activity offers valuable insights into protection levels, yet assay complexity limits its large-scale evaluation. In this study, we aimed to evaluate the persistence of cellular immunity following COVID-19 mRNA vaccination and to assess its relationship with breakthrough infection severity. We used the streamlined, high-throughput ex vivo activation of genes in leukocytes (EAGL) assay to assess T-cell responses in blood samples from vaccinated Japanese donors by tracking immunity at intervals post-vaccination. Vaccine-induced cellular immunity persisted longer than the antibody titers. Notably, lower antibody titers tended to precede infection, whereas cellular immune responses did not correlate with the occurrence of breakthrough infection in our cohort. However, among breakthrough cases, asymptomatic donors showed a trend toward higher Th1/CD8+ T-cell cytokine responses (IFNG, IL2, TNFSF2) than those with mild symptoms, although these differences did not reach statistical significance. Transcriptome analysis identified CXCL9 as a potential novel marker for disease outcome, with reduced expression correlating with persistent symptoms. Interestingly, in individuals ≥55 years old, Th1/CD8+ T cell cytokine expression decreased significantly and CXCL9 expression fell below the threshold associated with persistent symptoms. By contrast, we did not observe a consistent age-related decline in humoral measures. Overall, our findings suggest that cellular immune readouts, particularly IFNG in combination with CXCL9, may serve as exploratory correlates of vaccine-mediated symptom attenuation. Furthermore, the EAGL assay constitutes an efficient and scalable platform for high-throughput assessment of vaccine-induced cellular immunity, offering potential as a predictive tool for individual-level vaccine efficacy in mitigating symptoms.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Saito T, Couzinet A, Suzuki T, et al. Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms. Vaccine. 2025. PMID: 41202608. doi:10.1016/j.vaccine.2025.127942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。